Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression.
CONCLUSIONS: In pediatric solid tumor xenografts, nal-IRI demonstrated higher systemic and tumor exposures to SN-38 and improved antitumor activity compared with the current clinical formulation of irinotecan. Clinical studies of nal-IRI in pediatric solid tumors (especially EFT) and correlative studies to determine if SLFN11 expression can serve as a biomarker to predict nal-IRI clinical activity are warranted. Clin Cancer Res; 21(5); 1139-50. ©2015 AACR.
PMID: 25733708 [PubMed - in process]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP Tags: Clin Cancer Res Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Ewing's Sarcoma | Nanotechnology | Neuroblastoma | Neurology | Pediatrics | Rhabdomyosarcoma | Sarcomas | Study